Stockreport

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings, Inc.  (BPTH) 
Last bio-path holdings, inc. earnings: 11/14 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: biopathholdings.com
PDF Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Prog [Read more]